EYEiji Yoshihara

Eiji Yoshihara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eiji Yoshihara has a total of 142 co-authors. Here are the top co-authors by number of shared publications:

  • Jinhyuk Choi

    Lundquist Institute for Biomedical Innovation, Harbor-UCLA Medical Center, Torrance, USA

    5 shared publications
  • Fritz Cayabyab

    The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA

    4 shared publications
  • Harvey Perez

    The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA

    2 shared publications
  • Jinhyuk Choi

    The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA

    2 shared publications
  • Meghan Tahbaz

    The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA

    2 shared publications
  • Tae Gyu Oh

    Department of Oncology Science, College of Medicine, University of Oklahoma Health Campus, Oklahoma City, OK, USA

    2 shared publications

Latest Publications

  • The metabolic road from α-cells to β-cells

    by Yu Hamba, Jinhyuk Choi, Eiji Yoshihara

  • Open Access

    Spatial transcriptome mapping identifies Ppara-Anxa2 cross-talk in microplastic-induced hepatotoxicity

    by Woncheol Jung, Hassan Abushukair, Nikhil Y. Patil, Felix Ampadu, Maryam Firouzi, Iulia Rus, Jinhyuk Choi, Sree Deepthi Muthukrishnan, Surendra Shukla, Stefano Tarantini, et al.

    Microplastics (MPs) are increasingly recognized as an urgent global health concern, with mounting evidence linking their bioaccumulation to chronic disease risks. The liver, as a central organ for metabolic homeostasis and detoxification, is particularly sensitive to sustained MP exposure. However, the mechanisms underlying hepatic responses to polyethylene (PE), the most prevalent yet relatively understudied plastic type, remain poorly defined. By performing combined bulk and spatial transcriptomic analyses, we observed that PE resulted in hepatic dysfunction in mice fed on standard or metabolic dysfunction-associated steatohepatitis (MASH)–inducing diets, driving both globally and spatially distinct transcriptional alterations, including a nuclear receptor (NR), Ppara . Spatial transcriptomics uncovered the cell type heterogeneity and gene expression patterns masked in bulk analyses. Spatial clustering uncovered inflammatory hotspots characterized by reduced cellular diversity and distinct PE-responsive gene signatures. Among these, NR signaling emerged as a key regulatory axis, with Ppara identified as a modulator. We further demonstrated that Ppara regulates Anxa2 , a gene involved in damage response and tissue recovery, through enhancer and promoter binding. These findings offer insights into how PE disrupts hepatic homeostasis and underscores the value of spatial transcriptomics in elucidating environmental impacts on tissue organization and gene expression regulation. This study provides a molecular framework for understanding MP-associated disruption of liver pathophysiology and highlights potential targets for therapeutic intervention.


  • Open Access

    FXR and BET signaling orchestrate to protect β cells

    by Fritz Cayabyab, Jalan Tipirneni, David Chen, Jinhyuk Choi, Yu Hamba, Nhi Pham, Clarissa Tacto, Jie Wu, Liu Wang, Yeva Mirzakhanyan, et al.

    In both type 1 and type 2 diabetes (T1D and T2D), insulin-producing β cells undergo progressive dysfunction due to inflammation, leading to impaired glucose responsiveness, dedifferentiation, and cell loss. While bile acid (BA) dysregulation under diabetic conditions is known to influence metabolic and inflammatory pathways, its mechanistic role in β cell regulation remains incompletely defined 1–3 . Here we show that bile acid sensor Farnesoid X receptor (FXR) and Bromodomain and Extra-Terminal motif (BET) signaling cooperatively regulates β cell inflammatory response and β cell identity. We identified the physiological protein-protein interaction between FXR and the bromodomain-containing protein 4 (BRD4) as a regulatory axis that protects against β cell dysfunction. We show that FXR activation by Fexaramine (Fex) together with BRD4 inhibition by JQ1 synergistically suppressed IL-1β-induced inflammation while also improving β cell identity and insulin secretion in both db/db model and high-fat diet (HFD) plus multi low-dose streptozotocin (MLD-STZ) model of diabetes. Importantly, this cooperative effect is abolished in β cell–specific FXR knockout (βFXRKO) mice, establishing that FXR is required for the functional synergy between these pathways in vivo . Mechanistically, structure-guided modeling and mutational analyses identified a direct interaction between FXR and the BD2 domain of BRD4, depending on specific lysine acetylation sites. Additionally, inhibition of the BD2 domain of BET combined with FXR activation markedly improved β cell survival in human T1D and T2D models established from human pluripotent stem cell (hPSC)-derived islet-like organoids (HILOs). Collectively, these findings establish a BA–bromodomain axis as a transcriptional interface linking metabolic signaling and chromatin regulation, and highlight FXR–BET targeting as a promising strategy to counter progressive β cell failure in diabetes.

  • Open Access

    FXYD2 marks and regulates maturity of β cells via ion channel-mediated signal transduction

    by Clarissa Tacto, Meghan Tahbaz, Andrew Salib, Shudi Wang, Fritz Cayabyab, Jinhyuk Choi, Kiyoka Kim, Yu Hamba, Harvey Perez, Paul D. Gershon, et al.

    Human pancreatic islets regulate organ development and metabolic homeostasis, with dysfunction leading to diabetes. Human pluripotent stem cells (hPSCs) provide a potential alternative source to cadaveric human pancreatic islets for replacement therapy in diabetes. However, human islet-like organoids (HILOs) generated from hPSCs in vitro often exhibit heterogeneous immature phenotypes such as aberrant gene expression and inadequate insulin secretion in response to glucose. Here we show that FXYD Domain Containing Ion Transport Regulator 2 (FXYD2) marks and regulates functional maturation and heterogeneity of generated HILOs, by controlling the β cell transcriptome necessary for glucose-stimulated insulin secretion (GSIS). Despite its presence in mature β cells, FXYD2 is diminished in hPSC-derived β-like cells. Mechanistically, we find that FXYD2 physically interacts with SRC proto-oncogene, non-receptor tyrosine kinase (SRC) protein to regulate FXYD2-SRC-TEAD1 signaling to modulate β cell transcriptome. We demonstrate that FXYD2High HILOs significantly outperform FXYD2Low counterparts to improve hyperglycemia in STZ-induced diabetic immune deficient mice. These results suggest that FXYD2 marks and regulates human β cell maturation via channel-sensing signal transduction and that it can be used as a selection marker for functional heterogeneity of stem cell derived human islet organoids.


  • Open Access

    Insulin-producing cells derived from expandable stem cell-derived endoderm are effective for the treatment of type 2 diabetes

    by Eiji Yoshihara

    Insulin-producing cells derived from expandable stem cell-derived endoderm are effective for the treatment of type 2 diabetes


  • Open Access

    Scaling Insulin-Producing Cells by Multiple Strategies

    by Jinhyuk Choi, Fritz Cayabyab, Harvey Perez, Eiji Yoshihara

    In the quest to combat insulin-dependent diabetes mellitus (IDDM), allogenic pancreatic islet cell therapy sourced from deceased donors represents a significant therapeutic advance. However, the applicability of this approach is hampered by donor scarcity and the demand for sustained immunosuppression. Human induced pluripotent stem cells are a game-changing resource for generating synthetic functional insulin-producing β cells. In addition, novel methodologies allow the direct expansion of pancreatic progenitors and mature β cells, thereby circumventing prolonged differentiation. Nevertheless, achieving practical reproducibility and scalability presents a substantial challenge for this technology. As these innovative approaches become more prominent, it is crucial to thoroughly evaluate existing expansion techniques with an emphasis on their optimization and scalability. This manuscript delineates these cutting-edge advancements, offers a critical analysis of the prevailing strategies, and underscores pivotal challenges, including cost-efficiency and logistical issues. Our insights provide a roadmap, elucidating both the promises and the imperatives in harnessing the potential of these cellular therapies for IDDM.


  • Redoxisome Update: TRX and TXNIP/TBP2-Dependent Regulation of NLRP-1/NLRP-3 Inflammasome

    by Eiji Yoshihara, Yoshiyuki Matsuo, So Masaki, Zhe Chen, Hai Tian, Hiroshi Masutani, Akira Yamauchi, Kiichi Hirota, Junji Yodoi

    Recent studies have provided evidence for the direct binding of thioredoxin-1 (TRX1) to a component of inflammasome complex NLR family pyrin domain containing 1 (NLRP-1). This interaction suggests a potential role for TRX1 in the regulation of the NLRP-1 inflammasome. Furthermore, the NLRP-3 inflammasome is known to bind TRX1 and its inhibitor, TRX-binding protein-2/TRX-interacting protein/vitamin D3 upregulated protein-1 (TBP2/TXNIP/VDUP-1). This binding forms a redox-sensitive complex, termed the “Redoxisome,” as described previously. However, the specific functions of NLRP-1 within the redoxisome complex remain undefined. Antioxid. Redox Signal. 40, 595–597.


  • A guide from the stomach to β cells

    by Jinhyuk Choi, Fritz Cayabyab, Eiji Yoshihara


  • Open Access

    Stem Cell-Derived Islets for Type 2 Diabetes

    by Andrew Salib, Fritz Cayabyab, Eiji Yoshihara

    Since the discovery of insulin a century ago, insulin injection has been a primary treatment for both type 1 (T1D) and type 2 diabetes (T2D). T2D is a complicated disea se that is triggered by the dysfunction of insulin-producing β cells and insulin resistance in peripheral tissues. Insulin injection partially compensates for the role of endogenous insulin which promotes glucose uptake, lipid synthesis and organ growth. However, lacking the continuous, rapid, and accurate glucose regulation by endogenous functional β cells, the current insulin injection therapy is unable to treat the root causes of the disease. Thus, new technologies such as human pluripotent stem cell (hPSC)-derived islets are needed for both identifying the key molecular and genetic causes of T2D and for achieving a long-term treatment. This perspective review will provide insight into the efficacy of hPSC-derived human islets for treating and understanding T2D. We discuss the evidence that β cells should be the primary target for T2D treatment, the use of stem cells for the modeling of T2D and the potential use of hPSC-derived islet transplantation for treating T2D.


  • Open Access

    Adapting Physiology in Functional Human Islet Organogenesis

    by Eiji Yoshihara

    Generation of three-dimensional (3D)-structured functional human islets is expected to be an alternative cell source for cadaveric human islet transplantation for the treatment of insulin-dependent diabetes. Human pluripotent stem cells (hPSCs), such as human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), offer infinite resources for newly synthesized human islets. Recent advancements in hPSCs technology have enabled direct differentiation to human islet-like clusters, which can sense glucose and secrete insulin, and those islet clusters can ameliorate diabetes when transplanted into rodents or non-human primates (NHPs). However, the generated hPSC-derived human islet-like clusters are functionally immature compared with primary human islets. There remains a challenge to establish a technology to create fully functional human islets in vitro, which are functionally and transcriptionally indistinguishable from cadaveric human islets. Understanding the complex differentiation and maturation pathway is necessary to generate fully functional human islets for a tremendous supply of high-quality human islets with less batch-to-batch difference for millions of patients. In this review, I summarized the current progress in the generation of 3D-structured human islets from pluripotent stem cells and discussed the importance of adapting physiology for in vitro functional human islet organogenesis and possible improvements with environmental cues.